Articles

The ills inflicted by poor strategy

21st November 2014

The ills inflicted by poor strategy Candice O’Sullivan

If brand managers adopt a policy of 'doing no harm', as doctors do, then strategies will be taken seriously and the outcomes will be the best possible, for the brand... Read more

Facebook and pharma in 2014

20th November 2014

Facebook and pharma in 2014Stefan Marcus

Ten years on, Facebook remains an important channel through which pharma can engage with patients. What has been learned in that time and how have communication strategies evolved within the... Read more

'Efficiency-driven' M&A is here to stay, says Shire chief

19th November 2014

'Efficiency-driven' M&A is here to stay, says Shire chiefAndrew McConaghie

Andrew McConaghie reports on contrasting views on 2014's merger and acquisition rollercoaster ride, and the forces propelling it. The annual pharma / biotech sector conference hosted by the Financial Times usually yields... Read more

AZ points to potential in cancer at strategy update

19th November 2014

AZ points to potential in cancer at strategy updateStaff reporter

AstraZeneca (AZ) predicted yesterday that its "industry-leading" cancer portfolio would account for a quarter of its revenues in 2023 and is now considered its sixth growth platform.Just six months ago... Read more

News

RB spin-out Indivior says addiction pipeline will deliver

21st November 2014

RB spin-out Indivior says addiction pipeline will deliverStaff reporter

Earlier this week, Reckitt Benckiser (RB) made good on its promise to spin-out its pharmaceutical business into a new speciality drugmaker - to be called Indivior - that should be... Read more

Novartis novel psoriasis treatment gains positive opinion in Europe

21st November 2014

Novartis novel psoriasis treatment gains positive opinion in Europe Linda Banks

Novartis' Cosentyx (secukinumab) is the first IL-17A inhibitor to receive a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) as a first-line... Read more

UK aims to shave years off drug development

21st November 2014

UK aims to shave years off drug developmentAndrew McConaghie

The UK government has announced an 'end to end' review of how drugs are developed, approved and accessed by patients in a bid to make the country a leader in... Read more

Stratified medicine shows promise for NHS

20th November 2014

Stratified medicine shows promise for NHSLinda Banks

New research from the Association of the British Pharmaceutical Industry (ABPI) shows that 90 per cent of clinicians and other health professionals surveyed believe that stratified medicine will positively impact... Read more

Audio & Video

Dec 8th: Live webinar - The Price is Rig…

Slide-300x200b

 

With challenges to highly priced rare disease medicines and the Cancer Drug Fund evolving (final changes to be announced in the coming... View more

Now on demand - real world insight into …

The Diabetes Debate

 

Now available on demand (free to access) - originally broadcast on October 29th 2014.


Non-adherence to self-management regimens in diabetes is globally... View more

On-demand webinar: Is pharma brand marke…

Kantar Health webinar


While pharma observers speculate on the death of outdated drug discovery and sales models, some critical wounds to... View more

View the conversation - Tweetchat: Manag…

Atlantis Healthcare diabetes Tweetchat


Working in partnership, Atlantis Healthcare and pharmaphorum conducted a Tweetchat focussed on the real world challenges patients face in managing... View more

White Papers

Healthcare Innovation: the big ideas sha…

Healthcare Innovation: the big ideas shaping the future of pharmaDavid Rowley

The transformation taking place in healthcare is challenging for everyone and adaptability is key for the pharma industry's continued success.

Long production cycles, concentration on specialist drugs with high... View info

Giving a voice to those with heart valve…

Giving a voice to those with heart valve disease

Although over a million people in the UK today have heart valve disease, it remains an overlooked condition. Despite the priority being given to cardiovascular disease in the UK, it... View info

Pricing & Market Access Outlook 2014

Pricing & Market Access Outlook 2014

Pricing and market access are key issues for the pharma industry as healthcare budgets continue to tighten and the value of innovative drugs, particularly in areas of high unmet need,... View info

Getting the most out of technology for m…

Getting the most out of technology for multichannel marketing

While every pharma company recognises the potential of multichannel marketing to optimize its engagement with prescribers, many are yet to implement it to maximum potential. IMS Health explains how a... View info

Further News & Articles

Shire moves 500 jobs to Massachusetts

An efficiency programme begun at Shire before the AbbVie takeover bid has now resumed, with 500 jobs being re... Read more

News

Gilead once-daily hep C drug approved in Europe

The European Commission (EC) has granted marketing authorisation (MA) for Gilead Sciences' Harvoni (ledipasvi... Read more

News

Clovis set for showdown with AZ in lung cancer

Clovis Oncology has reported positive phase II results with lung cancer drug rociletinib that sets up a filing i... Read more

News

Pfizer-Merck cancer deal reduces likelihood of AZ merger

Pfizer has announced an agreement with Merck to co-develop a novel anti-PD-L1 antibody for various cancers.Read more

News

Tunnah’s musings: Defining medical influence and opinion leaders in a digital world

As information and connectivity have been democratised by social media and other online channels, Paul Tunnah muses ... Read more

Articles

Prevention and innovation key to tackling diabetes time bomb

The UK's plan to implement a national evidence-based diabetes prevention programme comes at a critical juncture,... Read more

News